1. Second Allogeneic Stem Cell Transplantation in Myeloid Malignancies.
- Author
-
Hartwig, Maite, Ocheni, Sunday, Asenova, Svetlana, Wiedemann, Bettina, Zabelina, Tatjana, Ayuk, Francis, Kabisch, Hartmut, Erttmann, Rudolf, Kröger, Nicolaus, Zander, Axel Rolf, and Bacher, Ulrike
- Subjects
STEM cell transplantation ,CELL transplantation ,MYELOID leukemia ,BONE marrow diseases ,NONLYMPHOID leukemia - Abstract
For patients with myeloid malignancies who relapse after allogeneic stem cell transplantation (allo-SCT), one salvage option is a second SCT. We retrospectively analyzed outcomes of the second allo-SCT in 25 patients who received at least 2 allografts from related/unrelated donors due to relapse of acute myeloid leukemia, myelodysplastic syndrome or myelofibrosis after the first SCT. A minority of the acute myeloid leukemia/myelodysplastic syndrome patients had reached complete hematological remission before the second SCT (6/25, 24%). Reduced conditioning strategies were performed in the majority (n = 23). Complete remission was achieved in all 21 cases with available data after the second SCT, but relapse was seen in 11/25 patients (44%). After a median follow-up of 18 months (range 6–47), 8/25 patients (32%) were still alive, and of those, 6 (24%) were in stable remission. In 9 cases mortality was associated to relapse and in 8 cases to transplant-related causes (treatment-related mortality; 8/25, 32%). In conclusion, a second SCT offers the chance of stable remission for some patients relapsing with a myeloid malignancy after a first allo-SCT, although high treatment-related mortality and relapse rates remain a problem. Efforts should concentrate on an optimization of conditioning strategies, immunosuppression and post-transplant surveillance for this specific situation. Copyright © 2009 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF